Share Price and Basic Stock Data
Last Updated: December 31, 2025, 9:17 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Centenial Surgical Suture Ltd operates within the medical equipment and accessories sector, focusing on surgical sutures. As of September 2023, the company reported a price of ₹104, with a market capitalization of ₹37.9 Cr. The revenue figures for the most recent quarters indicate stability, with sales recorded at ₹13.01 Cr in September 2022, slightly increasing to ₹13.66 Cr by June 2023. However, by September 2023, sales dipped to ₹13.10 Cr before recovering to ₹14.27 Cr in September 2024. Over the trailing twelve months, total sales stood at ₹51.91 Cr, with a slight annual decline from ₹52.66 Cr in March 2023 to ₹51.19 Cr in March 2024. This trend reflects a modest fluctuation in demand, indicating potential market challenges. Nevertheless, the overall revenue trajectory demonstrates resilience, supported by a consistent product offering in a growing healthcare sector.
Profitability and Efficiency Metrics
Centenial Surgical Suture Ltd’s profitability metrics present a mixed picture. The operating profit margin (OPM) stood at 10.33% as of September 2023, showcasing an improvement from previous quarters, particularly a jump to 15.48% in March 2025. However, net profit figures reveal a troubling trend, with reported losses of ₹2.08 Cr for the fiscal year ending March 2025, contrasting with a profit of ₹0.89 Cr in March 2023. The interest coverage ratio (ICR) recorded at 1.70x indicates limited capacity to cover interest expenses but remains above typical sector thresholds. The cash conversion cycle (CCC) of 895.19 days is significantly high, suggesting inefficiencies in inventory management and receivables collection. Overall, while there are improvements in operating margins, the substantial net losses and high CCC highlight critical areas needing management focus to enhance profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Centenial Surgical Suture Ltd reflects a challenging financial position. As of March 2025, total borrowings rose to ₹30.01 Cr, up from ₹9.92 Cr in March 2023, indicating increased leverage. The debt-to-equity ratio stood at 0.39, suggesting moderate financial risk. Reserves were reported at ₹25.27 Cr, providing a cushion against operational volatility. The book value per share was ₹56.70, representing a decline from the previous year, and the price-to-book value ratio of 1.94x is slightly above the sector average, indicating potential overvaluation. The current ratio of 1.98x presents a solid liquidity position, while the quick ratio of 0.61x raises concerns about immediate liquidity. In summary, while the company maintains a reasonable liquidity profile, the rising debt levels and declining book value necessitate careful monitoring of financial health.
Shareholding Pattern and Investor Confidence
Centenial Surgical Suture Ltd’s shareholding pattern indicates a balanced ownership structure, with promoters holding 46.89% and the public holding 53.11% as of September 2025. This distribution reflects a significant level of public interest, with the number of shareholders increasing from 911 in December 2022 to 1,193 by September 2025, suggesting growing investor confidence. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may limit external validation of the company’s prospects. The stability in promoter holding, which has remained consistent over recent quarters, signals a commitment to the company’s long-term growth. Nevertheless, the lack of institutional backing could be perceived as a risk, potentially affecting the stock’s liquidity and market perception. Overall, the shareholding pattern indicates a healthy level of retail investor engagement but raises questions about institutional interest.
Outlook, Risks, and Final Insight
The outlook for Centenial Surgical Suture Ltd hinges on its ability to navigate current operational challenges and enhance profitability. The company faces several risks, including rising debt levels, which could strain cash flows, and a high cash conversion cycle that may hinder operational efficiency. Additionally, the significant decline in net profits raises concerns about sustainability in a competitive market. However, the steady revenue generation and improving operating margins present opportunities for recovery. To strengthen its financial position, the company may need to focus on optimizing inventory management and enhancing sales strategies. Should Centenial Surgical Suture Ltd successfully address these challenges, it could unlock growth potential, yet failure to do so may lead to continued financial distress. Investors should closely watch management’s strategic initiatives to gauge the company’s future trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Constronics Infra Ltd | 76.4 Cr. | 61.0 | 123/46.0 | 17.4 | 32.8 | 0.00 % | 19.7 % | 15.8 % | 10.0 |
| Centenial Surgical Suture Ltd | 37.5 Cr. | 103 | 189/82.2 | 84.1 | 0.00 % | 3.94 % | 4.64 % | 10.0 | |
| Adeshwar Meditex Ltd | 23.1 Cr. | 16.0 | 26.5/14.0 | 11.2 | 26.1 | 0.00 % | 8.27 % | 5.51 % | 10.0 |
| Poly Medicure Ltd | 17,985 Cr. | 1,774 | 2,938/1,683 | 49.7 | 288 | 0.20 % | 20.1 % | 15.8 % | 5.00 |
| Mohini Health & Hygiene Ltd | 71.4 Cr. | 39.2 | 86.9/37.9 | 21.4 | 55.7 | 0.00 % | 14.1 % | 10.0 % | 10.0 |
| Industry Average | 17,985.00 Cr | 398.64 | 24.93 | 97.34 | 0.04% | 13.22% | 10.35% | 9.00 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.01 | 13.13 | 13.02 | 13.66 | 13.10 | 12.38 | 12.05 | 13.74 | 14.27 | 12.20 | 13.31 | 12.94 | 13.46 |
| Expenses | 11.98 | 12.06 | 11.92 | 12.50 | 11.96 | 11.19 | 10.54 | 12.02 | 12.54 | 11.45 | 11.25 | 11.71 | 12.07 |
| Operating Profit | 1.03 | 1.07 | 1.10 | 1.16 | 1.14 | 1.19 | 1.51 | 1.72 | 1.73 | 0.75 | 2.06 | 1.23 | 1.39 |
| OPM % | 7.92% | 8.15% | 8.45% | 8.49% | 8.70% | 9.61% | 12.53% | 12.52% | 12.12% | 6.15% | 15.48% | 9.51% | 10.33% |
| Other Income | 0.08 | 0.02 | 0.03 | 0.01 | 0.02 | 0.06 | 0.03 | 0.00 | 0.06 | 0.01 | 0.05 | 0.00 | 0.05 |
| Interest | 0.39 | 0.39 | 0.52 | 0.48 | 0.52 | 0.51 | 0.95 | 0.53 | 0.53 | 0.50 | 2.19 | 0.32 | 0.46 |
| Depreciation | 0.31 | 0.34 | 0.31 | 0.30 | 0.32 | 0.33 | 0.44 | 0.79 | 1.09 | 1.11 | 1.26 | 0.95 | 0.99 |
| Profit before tax | 0.41 | 0.36 | 0.30 | 0.39 | 0.32 | 0.41 | 0.15 | 0.40 | 0.17 | -0.85 | -1.34 | -0.04 | -0.01 |
| Tax % | 26.83% | 22.22% | 53.33% | 25.64% | 28.12% | 24.39% | -26.67% | 25.00% | 23.53% | 0.00% | -11.19% | 0.00% | 0.00% |
| Net Profit | 0.30 | 0.28 | 0.14 | 0.29 | 0.24 | 0.31 | 0.19 | 0.30 | 0.13 | -0.85 | -1.18 | -0.04 | -0.01 |
| EPS in Rs | 0.82 | 0.77 | 0.38 | 0.79 | 0.66 | 0.85 | 0.52 | 0.82 | 0.36 | -2.33 | -3.23 | -0.11 | -0.03 |
Last Updated: December 27, 2025, 3:02 pm
Below is a detailed analysis of the quarterly data for Centenial Surgical Suture Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 13.46 Cr.. The value appears strong and on an upward trend. It has increased from 12.94 Cr. (Jun 2025) to 13.46 Cr., marking an increase of 0.52 Cr..
- For Expenses, as of Sep 2025, the value is 12.07 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.71 Cr. (Jun 2025) to 12.07 Cr., marking an increase of 0.36 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.39 Cr.. The value appears strong and on an upward trend. It has increased from 1.23 Cr. (Jun 2025) to 1.39 Cr., marking an increase of 0.16 Cr..
- For OPM %, as of Sep 2025, the value is 10.33%. The value appears strong and on an upward trend. It has increased from 9.51% (Jun 2025) to 10.33%, marking an increase of 0.82%.
- For Other Income, as of Sep 2025, the value is 0.05 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Jun 2025) to 0.05 Cr., marking an increase of 0.05 Cr..
- For Interest, as of Sep 2025, the value is 0.46 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.32 Cr. (Jun 2025) to 0.46 Cr., marking an increase of 0.14 Cr..
- For Depreciation, as of Sep 2025, the value is 0.99 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.95 Cr. (Jun 2025) to 0.99 Cr., marking an increase of 0.04 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.01 Cr.. The value appears strong and on an upward trend. It has increased from -0.04 Cr. (Jun 2025) to -0.01 Cr., marking an increase of 0.03 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -0.01 Cr.. The value appears strong and on an upward trend. It has increased from -0.04 Cr. (Jun 2025) to -0.01 Cr., marking an increase of 0.03 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.03. The value appears strong and on an upward trend. It has increased from -0.11 (Jun 2025) to -0.03, marking an increase of 0.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:59 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 50.96 | 51.71 | 51.39 | 52.84 | 52.73 | 56.05 | 55.61 | 36.93 | 44.43 | 52.66 | 51.19 | 53.49 | 51.91 |
| Expenses | 46.39 | 46.47 | 46.71 | 47.95 | 48.26 | 50.64 | 49.68 | 31.82 | 39.94 | 48.26 | 46.04 | 47.07 | 46.48 |
| Operating Profit | 4.57 | 5.24 | 4.68 | 4.89 | 4.47 | 5.41 | 5.93 | 5.11 | 4.49 | 4.40 | 5.15 | 6.42 | 5.43 |
| OPM % | 8.97% | 10.13% | 9.11% | 9.25% | 8.48% | 9.65% | 10.66% | 13.84% | 10.11% | 8.36% | 10.06% | 12.00% | 10.46% |
| Other Income | 0.04 | 0.10 | 0.02 | 0.01 | 0.05 | 0.02 | 0.09 | 0.09 | 0.04 | 0.13 | 0.13 | 0.12 | 0.11 |
| Interest | 1.31 | 1.61 | 1.65 | 1.77 | 1.51 | 1.89 | 2.31 | 2.12 | 1.93 | 1.77 | 2.62 | 3.90 | 3.47 |
| Depreciation | 0.59 | 0.83 | 0.68 | 0.59 | 0.60 | 0.69 | 1.55 | 1.55 | 1.53 | 1.30 | 1.39 | 4.25 | 4.31 |
| Profit before tax | 2.71 | 2.90 | 2.37 | 2.54 | 2.41 | 2.85 | 2.16 | 1.53 | 1.07 | 1.46 | 1.27 | -1.61 | -2.24 |
| Tax % | 33.95% | 34.14% | 34.18% | 32.68% | 36.10% | 29.12% | 39.81% | 37.25% | 42.06% | 39.73% | 11.02% | -9.32% | |
| Net Profit | 1.79 | 1.92 | 1.56 | 1.72 | 1.54 | 2.02 | 1.30 | 0.96 | 0.63 | 0.89 | 1.13 | -1.46 | -2.08 |
| EPS in Rs | 4.91 | 5.26 | 4.28 | 4.71 | 4.22 | 5.54 | 3.56 | 2.63 | 1.73 | 2.44 | 3.10 | -4.00 | -5.70 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 7.26% | -18.75% | 10.26% | -10.47% | 31.17% | -35.64% | -26.15% | -34.38% | 41.27% | 26.97% | -229.20% |
| Change in YoY Net Profit Growth (%) | 0.00% | -26.01% | 29.01% | -20.72% | 41.63% | -66.81% | 9.49% | -8.22% | 75.64% | -14.30% | -256.17% |
Centenial Surgical Suture Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -1% |
| 3 Years: | 6% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -287% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 23% |
| 3 Years: | 29% |
| 1 Year: | -1% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | -5% |
Last Updated: September 5, 2025, 2:51 pm
Balance Sheet
Last Updated: December 4, 2025, 2:36 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 |
| Reserves | 13.83 | 15.79 | 17.35 | 19.07 | 20.62 | 22.63 | 23.18 | 24.15 | 24.77 | 25.66 | 26.79 | 25.33 | 25.27 |
| Borrowings | 11.32 | 12.28 | 13.11 | 15.24 | 14.37 | 13.10 | 12.72 | 13.47 | 9.30 | 9.92 | 23.24 | 30.01 | 10.81 |
| Other Liabilities | 19.53 | 21.80 | 16.68 | 16.07 | 14.89 | 15.61 | 27.96 | 27.00 | 21.85 | 25.40 | 23.70 | 23.83 | 41.78 |
| Total Liabilities | 50.10 | 55.29 | 52.56 | 55.80 | 55.30 | 56.76 | 69.28 | 70.04 | 61.34 | 66.40 | 79.15 | 84.59 | 83.28 |
| Fixed Assets | 4.53 | 4.13 | 3.64 | 3.71 | 3.80 | 4.08 | 10.44 | 8.97 | 7.60 | 6.46 | 12.77 | 19.99 | 18.68 |
| CWIP | 0.19 | 0.19 | 0.19 | 0.19 | 0.22 | 0.22 | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 45.38 | 50.97 | 48.73 | 51.90 | 51.28 | 52.46 | 58.62 | 61.07 | 53.74 | 59.94 | 66.38 | 64.60 | 64.60 |
| Total Assets | 50.10 | 55.29 | 52.56 | 55.80 | 55.30 | 56.76 | 69.28 | 70.04 | 61.34 | 66.40 | 79.15 | 84.59 | 83.28 |
Below is a detailed analysis of the balance sheet data for Centenial Surgical Suture Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 5.42 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.42 Cr..
- For Reserves, as of Sep 2025, the value is 25.27 Cr.. The value appears to be declining and may need further review. It has decreased from 25.33 Cr. (Mar 2025) to 25.27 Cr., marking a decrease of 0.06 Cr..
- For Borrowings, as of Sep 2025, the value is 10.81 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 30.01 Cr. (Mar 2025) to 10.81 Cr., marking a decrease of 19.20 Cr..
- For Other Liabilities, as of Sep 2025, the value is 41.78 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 23.83 Cr. (Mar 2025) to 41.78 Cr., marking an increase of 17.95 Cr..
- For Total Liabilities, as of Sep 2025, the value is 83.28 Cr.. The value appears to be improving (decreasing). It has decreased from 84.59 Cr. (Mar 2025) to 83.28 Cr., marking a decrease of 1.31 Cr..
- For Fixed Assets, as of Sep 2025, the value is 18.68 Cr.. The value appears to be declining and may need further review. It has decreased from 19.99 Cr. (Mar 2025) to 18.68 Cr., marking a decrease of 1.31 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 64.60 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 64.60 Cr..
- For Total Assets, as of Sep 2025, the value is 83.28 Cr.. The value appears to be declining and may need further review. It has decreased from 84.59 Cr. (Mar 2025) to 83.28 Cr., marking a decrease of 1.31 Cr..
Notably, the Reserves (25.27 Cr.) exceed the Borrowings (10.81 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -6.75 | -7.04 | -8.43 | -10.35 | -9.90 | -7.69 | -6.79 | -8.36 | -4.81 | -5.52 | -18.09 | -23.59 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 135.08 | 138.21 | 132.75 | 130.76 | 125.29 | 134.80 | 153.26 | 221.39 | 160.44 | 142.71 | 134.05 | 125.56 |
| Inventory Days | 297.67 | 350.07 | 365.93 | 468.59 | 465.89 | 434.68 | 483.86 | 1,276.44 | 599.23 | 677.26 | 909.72 | 921.61 |
| Days Payable | 162.36 | 167.34 | 124.26 | 146.28 | 135.64 | 120.26 | 187.98 | 372.75 | 159.00 | 222.42 | 207.75 | 151.98 |
| Cash Conversion Cycle | 270.39 | 320.94 | 374.42 | 453.06 | 455.54 | 449.22 | 449.14 | 1,125.08 | 600.67 | 597.56 | 836.02 | 895.19 |
| Working Capital Days | 122.62 | 127.27 | 148.80 | 156.25 | 164.05 | 167.69 | 172.36 | 282.37 | 236.68 | 207.73 | 226.67 | 210.99 |
| ROCE % | 13.25% | 14.08% | 11.59% | 11.40% | 9.78% | 11.62% | 10.84% | 8.65% | 7.27% | 8.03% | 8.07% | 3.94% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -4.01 | 3.11 | 2.43 | 1.72 | 2.64 |
| Diluted EPS (Rs.) | -4.01 | 3.11 | 2.43 | 1.72 | 2.64 |
| Cash EPS (Rs.) | 5.14 | 4.65 | 4.03 | 3.97 | 4.63 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 56.70 | 59.40 | 57.31 | 55.67 | 54.52 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 56.70 | 59.40 | 57.31 | 55.67 | 54.52 |
| Revenue From Operations / Share (Rs.) | 98.66 | 94.37 | 97.07 | 81.90 | 68.09 |
| PBDIT / Share (Rs.) | 11.77 | 9.46 | 8.16 | 8.28 | 9.40 |
| PBIT / Share (Rs.) | 3.92 | 6.90 | 5.76 | 5.47 | 6.54 |
| PBT / Share (Rs.) | -2.98 | 2.35 | 2.70 | 1.98 | 2.82 |
| Net Profit / Share (Rs.) | -2.70 | 2.09 | 1.63 | 1.16 | 1.77 |
| PBDIT Margin (%) | 11.92 | 10.02 | 8.40 | 10.11 | 13.80 |
| PBIT Margin (%) | 3.97 | 7.30 | 5.93 | 6.67 | 9.60 |
| PBT Margin (%) | -3.02 | 2.48 | 2.77 | 2.41 | 4.14 |
| Net Profit Margin (%) | -2.73 | 2.21 | 1.68 | 1.41 | 2.60 |
| Return on Networth / Equity (%) | -4.75 | 3.52 | 2.85 | 2.07 | 3.25 |
| Return on Capital Employeed (%) | 4.03 | 8.08 | 8.37 | 8.00 | 9.20 |
| Return On Assets (%) | -1.73 | 1.43 | 1.33 | 1.02 | 1.37 |
| Total Debt / Equity (X) | 0.39 | 0.44 | 0.31 | 0.30 | 0.41 |
| Asset Turnover Ratio (%) | 0.65 | 0.70 | 0.82 | 0.67 | 0.53 |
| Current Ratio (X) | 1.98 | 1.99 | 2.04 | 2.20 | 1.92 |
| Quick Ratio (X) | 0.61 | 0.69 | 0.76 | 0.86 | 0.77 |
| Inventory Turnover Ratio (X) | 1.24 | 0.50 | 0.58 | 0.45 | 0.46 |
| Interest Coverage Ratio (X) | 1.70 | 2.08 | 2.66 | 2.37 | 2.53 |
| Interest Coverage Ratio (Post Tax) (X) | 0.60 | 1.46 | 1.53 | 1.33 | 1.48 |
| Enterprise Value (Cr.) | 71.71 | 63.31 | 43.04 | 41.99 | 34.92 |
| EV / Net Operating Revenue (X) | 1.34 | 1.24 | 0.81 | 0.94 | 0.94 |
| EV / EBITDA (X) | 11.23 | 12.34 | 9.72 | 9.35 | 6.85 |
| MarketCap / Net Operating Revenue (X) | 1.11 | 0.96 | 0.63 | 0.74 | 0.62 |
| Price / BV (X) | 1.94 | 1.54 | 1.08 | 1.09 | 0.78 |
| Price / Net Operating Revenue (X) | 1.11 | 0.96 | 0.63 | 0.74 | 0.62 |
| EarningsYield | -0.02 | 0.02 | 0.02 | 0.01 | 0.04 |
After reviewing the key financial ratios for Centenial Surgical Suture Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -4.01. This value is below the healthy minimum of 5. It has decreased from 3.11 (Mar 24) to -4.01, marking a decrease of 7.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is -4.01. This value is below the healthy minimum of 5. It has decreased from 3.11 (Mar 24) to -4.01, marking a decrease of 7.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 5.14. This value is within the healthy range. It has increased from 4.65 (Mar 24) to 5.14, marking an increase of 0.49.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 56.70. It has decreased from 59.40 (Mar 24) to 56.70, marking a decrease of 2.70.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 56.70. It has decreased from 59.40 (Mar 24) to 56.70, marking a decrease of 2.70.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 98.66. It has increased from 94.37 (Mar 24) to 98.66, marking an increase of 4.29.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.77. This value is within the healthy range. It has increased from 9.46 (Mar 24) to 11.77, marking an increase of 2.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 3.92. This value is within the healthy range. It has decreased from 6.90 (Mar 24) to 3.92, marking a decrease of 2.98.
- For PBT / Share (Rs.), as of Mar 25, the value is -2.98. This value is below the healthy minimum of 0. It has decreased from 2.35 (Mar 24) to -2.98, marking a decrease of 5.33.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.70. This value is below the healthy minimum of 2. It has decreased from 2.09 (Mar 24) to -2.70, marking a decrease of 4.79.
- For PBDIT Margin (%), as of Mar 25, the value is 11.92. This value is within the healthy range. It has increased from 10.02 (Mar 24) to 11.92, marking an increase of 1.90.
- For PBIT Margin (%), as of Mar 25, the value is 3.97. This value is below the healthy minimum of 10. It has decreased from 7.30 (Mar 24) to 3.97, marking a decrease of 3.33.
- For PBT Margin (%), as of Mar 25, the value is -3.02. This value is below the healthy minimum of 10. It has decreased from 2.48 (Mar 24) to -3.02, marking a decrease of 5.50.
- For Net Profit Margin (%), as of Mar 25, the value is -2.73. This value is below the healthy minimum of 5. It has decreased from 2.21 (Mar 24) to -2.73, marking a decrease of 4.94.
- For Return on Networth / Equity (%), as of Mar 25, the value is -4.75. This value is below the healthy minimum of 15. It has decreased from 3.52 (Mar 24) to -4.75, marking a decrease of 8.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.03. This value is below the healthy minimum of 10. It has decreased from 8.08 (Mar 24) to 4.03, marking a decrease of 4.05.
- For Return On Assets (%), as of Mar 25, the value is -1.73. This value is below the healthy minimum of 5. It has decreased from 1.43 (Mar 24) to -1.73, marking a decrease of 3.16.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.39. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.39, marking a decrease of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has decreased from 0.70 (Mar 24) to 0.65, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.98. This value is within the healthy range. It has decreased from 1.99 (Mar 24) to 1.98, marking a decrease of 0.01.
- For Quick Ratio (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.69 (Mar 24) to 0.61, marking a decrease of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.24. This value is below the healthy minimum of 4. It has increased from 0.50 (Mar 24) to 1.24, marking an increase of 0.74.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.70. This value is below the healthy minimum of 3. It has decreased from 2.08 (Mar 24) to 1.70, marking a decrease of 0.38.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 3. It has decreased from 1.46 (Mar 24) to 0.60, marking a decrease of 0.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 71.71. It has increased from 63.31 (Mar 24) to 71.71, marking an increase of 8.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has increased from 1.24 (Mar 24) to 1.34, marking an increase of 0.10.
- For EV / EBITDA (X), as of Mar 25, the value is 11.23. This value is within the healthy range. It has decreased from 12.34 (Mar 24) to 11.23, marking a decrease of 1.11.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has increased from 0.96 (Mar 24) to 1.11, marking an increase of 0.15.
- For Price / BV (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has increased from 1.54 (Mar 24) to 1.94, marking an increase of 0.40.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has increased from 0.96 (Mar 24) to 1.11, marking an increase of 0.15.
- For EarningsYield, as of Mar 25, the value is -0.02. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to -0.02, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Centenial Surgical Suture Ltd:
- Net Profit Margin: -2.73%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.03% (Industry Average ROCE: 13.22%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -4.75% (Industry Average ROE: 10.35%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.6
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.61
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 24.93)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.39
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -2.73%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | F-29, MIDC, Murbad Thane Maharashtra 421401 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vijay Majrekar | Managing Director & CEO |
| Ms. Anuradha Kashikar | Executive Director & CFO |
| Mr. Devraj T Poojary | Executive Director |
| Mr. Neel M Vora | Ind. Non-Executive Director |
| Mr. Ridhima B Limaye | Ind. Non-Executive Director |
| Mr. Akash S Modi | Ind. Non-Executive Director |
| Mr. Anuj V Shah | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Centenial Surgical Suture Ltd?
Centenial Surgical Suture Ltd's intrinsic value (as of 31 December 2025) is ₹47.76 which is 53.63% lower the current market price of ₹103.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹37.5 Cr. market cap, FY2025-2026 high/low of ₹189/82.2, reserves of ₹25.27 Cr, and liabilities of ₹83.28 Cr.
What is the Market Cap of Centenial Surgical Suture Ltd?
The Market Cap of Centenial Surgical Suture Ltd is 37.5 Cr..
What is the current Stock Price of Centenial Surgical Suture Ltd as on 31 December 2025?
The current stock price of Centenial Surgical Suture Ltd as on 31 December 2025 is ₹103.
What is the High / Low of Centenial Surgical Suture Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Centenial Surgical Suture Ltd stocks is ₹189/82.2.
What is the Stock P/E of Centenial Surgical Suture Ltd?
The Stock P/E of Centenial Surgical Suture Ltd is .
What is the Book Value of Centenial Surgical Suture Ltd?
The Book Value of Centenial Surgical Suture Ltd is 84.1.
What is the Dividend Yield of Centenial Surgical Suture Ltd?
The Dividend Yield of Centenial Surgical Suture Ltd is 0.00 %.
What is the ROCE of Centenial Surgical Suture Ltd?
The ROCE of Centenial Surgical Suture Ltd is 3.94 %.
What is the ROE of Centenial Surgical Suture Ltd?
The ROE of Centenial Surgical Suture Ltd is 4.64 %.
What is the Face Value of Centenial Surgical Suture Ltd?
The Face Value of Centenial Surgical Suture Ltd is 10.0.